Invion Limited, a clinical-stage life-sciences company, develops photodynamic therapy for the treatment of various cancers in Australia. It develops IVX-P02 to treat skin cancers, as well as solid cancers, including lung, prostrate, and ovarian cancers; and IVX-MES, an intravenous treatment for mesothelioma. The company has a research and development alliance agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and partnership agreements with Formulytica and vivoPharm to develop and test IVX-P02 gel. Invion Limited also has a research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company is headquartered in Melbourne, Australia.